{"id":"W4387798496","doi":"10.1158/1078-0432.ccr-22-3627","title":"Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; McMaster University; BC Cancer Agency","funders":"EMD Serono; Genentech; Servier; Loxo Oncology; Astellas Pharma; Daiichi-Sankyo; Natera; National Center for Advancing Translational Sciences; Seagen; G1 Therapeutics; Sanofi; Exelixis; Jazz Pharmaceuticals; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Helsinn; CTI Biopharma; Gilead Sciences; Bristol-Myers Squibb; Myriad Genetics; AstraZeneca; Mereo BioPharma; Pfizer","keywords":"Medicine; Pharmacokinetics; Adverse effect; Nausea; Internal medicine; Tolerability; Oncology; Population; Cancer; Urology; Pharmacology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001230169,0.0009515565,0.00140607,0.0003333592,0.0003097668,0.0005948234,0.0005263356,0.0005977258,0.001752454],"category_scores_gemma":[0.0009375043,0.0004487588,0.0007715582,0.0003684386,0.0006778086,0.0005121939,0.000273982,0.002324129,0.0004359972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009589727,"about_ca_system_score_gemma":0.001057813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004676101,"about_ca_topic_score_gemma":0.001313854,"domain_scores_codex":[0.9995201,0.0002058908,0.00003452285,0.00009838698,0.00006706953,0.00007397904],"domain_scores_gemma":[0.9993625,0.00008996924,0.0001789971,0.00007549887,0.0000414775,0.0002516457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4938221,0.1116025,0.04563575,0.0006821057,0.001979506,0.0004381946,0.0008470221,0.009573927,0.1433133,0.0003144402,0.002897191,0.188894],"study_design_scores_gemma":[0.1860814,0.7337803,0.05804266,0.00003430681,0.0004431659,0.000584607,0.0001026377,0.003822417,0.01377665,0.000199311,0.003092885,0.00003956847],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981136,0.0004533737,0.0002265373,0.00007680585,0.00001665955,0.0005403557,0.000153967,0.00002680835,0.0003918406],"genre_scores_gemma":[0.9977411,0.0002237759,0.0006949324,0.0001688934,0.00002380477,0.0003742151,0.0003499902,0.000007867885,0.0004154062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001752454,"threshold_uncertainty_score":0.006957889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.173113370017172,"score_gpt":0.5108023116460696,"score_spread":0.3376889416288976,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}